Evaluative study between calculated and measured DVHs for advance techniques of radiotherapy for Prostate Cancer Patients

Abstract

This study aims to use 3DVH software (Sun Nuclear Corporation, Melbourne, FL, USA) to compare the dose that was predicted by treatment planning system (TPS) with the measured dose obtained by ArcCHECK dosimetric device using two advance treatment techniques: Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT). Thirty prostate cancer patients who were treated with VMAT and re- planned with IMRT using Eclipse planning system were studied. The percentage dose differences (%DDs) were calculated using 3DVH software for planning target volume (PTV) and risk organ (OARs). The correlations between %DD and the gamma pass rate (GPR) (3%/3mm, 2%/2mm and 1%/1mm) criterion were examined. Both the DVHs calculated by 3DVH and the one projected by TPS were compared using the different parameters for PTV and OAR. In VMAT technique, the %DD was less than 3% for PTV and 4% for OAR while the IMRT technique recorded %DD less than 2% for PTV and 4% for OAR. 3DVH was somewhat more consistent with the planned VMAT verification data compared to ArcCHECK, with a mean gamma pass rate of 99.34% for the 3%/3 mm criterion Based on our results, VMAT is especially beneficial for prostate most cancers treatment.

Keywords

• 3dvh
• qa
• arccheck
• gamma pass rate